BOSON BIOSCIENCE

Partnering Contact

BOSON BIOSCIENCE

Closed

Pipeline

Our Pipeline

Through its AI-powered BSP™ platform, BOSON Bioscience is
expanding a mechanism-based recombinant protein pipeline
centered on diseases with significant unmet medical needs.

  • Oncology | Anticancer Pipeline

    Recombinant protein therapeutics that precisely regulate pathological signaling in solid tumors
    • A mechanism-driven approach that modulates pathological signaling in the tumor microenvironment (TME) and ECM
    • Targeting signaling axes associated with metastasis and therapy resistance, including integrin–FAK–PI3K/AKT and NF-κB
    • A platform-based anticancer pipeline with potential for expansion across diverse solid tumors

  • Chronic Inflammation | Chronic Inflammation Pipeline

    Recombinant protein therapeutics that precisely regulate chronic inflammatory signaling pathways
    • Regulating upstream inflammatory signaling pathways commonly activated in chronic inflammatory diseases
    • Designed with disease-specific downstream responses in mind
    • An immune-modulation-based anti-inflammatory strategy considering safety and long-term applicability

BSP™ Platform Overview

All pipelines are developed through the AI-powered BSP™ platform and are currently in the preclinical stage.

Platform Code Indication Targets Pre-clinical Phase 1 Phase 2 Phase 3
AI-BSP™ BSP101 Atopic
Dermatitis (AD)		 AhR/ARNT ●
BSP105 Atherosclerosis ICAM-1/
VCAM-1		 ●
BSP201 Colon Cancer STAT3-
ZEB1-Sox2		 ●
BSP205 Triple-Negative
Breast Cancer		 FAK-PI3K-AKT ●
BSP211 Melanoma ITGAV/TIMP-1 ●